These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17692320)

  • 1. The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes.
    Laumen H; Skurk T; Hauner H
    Atherosclerosis; 2008 Feb; 196(2):565-73. PubMed ID: 17692320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rosuvastatin on fibrinolytic system of human umbilical vein endothelial cells in vitro.
    He F; Zhao J; Guo R; Liang Y
    Am J Med Sci; 2014 Oct; 348(4):319-23. PubMed ID: 24694789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1.
    Kang BY; Mehta JL
    J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):283-91. PubMed ID: 19724024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity.
    Swiatkowska M; Pawlowska Z; Szemraj J; Drzewoski J; Watala C; Cierniewski CS
    Jpn J Pharmacol; 2002 Dec; 90(4):337-44. PubMed ID: 12501010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh.
    Choi EY; Chang W; Lim S; Song BW; Cha MJ; Kim HJ; Choi E; Jang Y; Chung N; Hwang KC
    Eur J Pharmacol; 2010 Feb; 627(1-3):56-62. PubMed ID: 19883640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells.
    Lazzerini PE; Capperucci C; Spreafico A; Capecchi PL; Niccolini S; Ferrata P; Frediani B; Galeazzi M; Laghi-Pasini F
    Joint Bone Spine; 2013 Mar; 80(2):195-200. PubMed ID: 22999910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells.
    Kim YS; Ahn Y; Hong MH; Kim KH; Park HW; Hong YJ; Kim JH; Kim W; Jeong MH; Cho JG; Park JC; Kang JC
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):376-83. PubMed ID: 17577102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF-α modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes.
    Lobo SM; Quinto BM; Oyama L; Nakamichi R; Ribeiro AB; Zanella MT; Dalboni MA; Batista MC
    Cytokine; 2012 Oct; 60(1):150-6. PubMed ID: 22658637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
    Stalker TJ; Lefer AM; Scalia R
    Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells.
    Landsberger M; Jantzen F; Könemann S; Felix SB
    Biochem Biophys Res Commun; 2005 Nov; 336(4):1005-9. PubMed ID: 16165089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor.
    Kiyan J; Kusch A; Tkachuk S; Krämer J; Haller H; Dietz R; Smith G; Dumler I
    Atherosclerosis; 2007 Dec; 195(2):254-61. PubMed ID: 17275828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of HMG-CoA reductase inhibitor on experimental autoimmune myocarditis.
    Liu X; Li B; Wang W; Zhang C; Zhang M; Zhang Y; Xia Y; Dong Z; Guo Y; An F
    Cardiovasc Drugs Ther; 2012 Apr; 26(2):121-30. PubMed ID: 22382902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct effects of rosuvastatin on pancreatic human beta cells.
    Bugliani M; Syed F; Masini M; Marselli L; Suleiman M; Novelli M; Filipponi F; Boggi U; Masiello P; De Tata V; Marchetti P
    Acta Diabetol; 2013 Dec; 50(6):983-5. PubMed ID: 23503985
    [No Abstract]   [Full Text] [Related]  

  • 14. Hydroxymethylglutaryl--CoA reductase inhibitor inhibits induction of nitric oxide synthase in 3T3--L1 preadipocytes.
    Dobashi K; Araki S; Kubo K; Kawagoe R; Yamamoto Y; Shirahata A
    Life Sci; 2008 Jan; 82(1-2):85-90. PubMed ID: 18036617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents.
    Capra V; Rovati GE
    Pulm Pharmacol Ther; 2014 Feb; 27(1):10-6. PubMed ID: 23806820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosuvastatin inhibits pressure-induced fibrotic responses via the expression regulation of prostacyclin and prostaglandin E2 in rat renal tubular cells.
    Chen CH; Cheng CY; Chen YC; Sue YM; Hsu YH; Tsai WL; Chen TH
    Eur J Pharmacol; 2013 Jan; 700(1-3):65-73. PubMed ID: 23276663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes.
    Sakamoto K; Osaki M; Hozumi A; Goto H; Fukushima T; Baba H; Shindo H
    BMC Musculoskelet Disord; 2011 Apr; 12(1):82. PubMed ID: 21524281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung.
    Chang CC; Wang SS; Hsieh HG; Lee WS; Chuang CL; Lin HC; Lee FY; Lee SD; Huang HC
    Clin Sci (Lond); 2015 Sep; 129(6):449-60. PubMed ID: 25940601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.
    Takeshita Y; Takamura T; Hamaguchi E; Shimizu A; Ota T; Sakurai M; Kaneko S
    Metabolism; 2006 Nov; 55(11):1464-72. PubMed ID: 17046548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes.
    Pandey M; Loskutoff DJ; Samad F
    FASEB J; 2005 Aug; 19(10):1317-9. PubMed ID: 15928193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.